TD Cowen analyst Yaron Werber raised the firm’s price target on Ascendis Pharma (ASND) to $162 from $153 and keeps a Buy rating on the shares.

BofA lowered the firm’s price target on Ascendis Pharma (ASND) to $192 from $203 and keeps a Buy rating on the shares. After Ascendis provided ...

Wall St ends lower as White House says Trump to implement tariffs February 1, 2025 The U.S. Food and Drug Administration has approved Vertex Pharmaceuticals' drug to treat acute pain, the health ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Rua Dr. Diogo de Faria, 1087 – 9º andar – Vila Clementino 04037-003 São Paulo/SP - Brasil E-mail: [email protected] ...

TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company focused on developing novel therapies for treatment of cancer by targeting the tumor microenvironment (TME), ...

TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company focused on developing novel therapies for treatment of cancer by targeting the tumor microenvironment (TME ...

NORTHFIELD, Minn., Jan. 28, 2025 /PRNewswire/ -- Aurora Pharmaceutical, a leading manufacturer of animal health products, is excited to announce the appointment of Stephanie Hastings as its new ...

NORTHFIELD, Minn., Jan. 28, 2025 /PRNewswire/ -- Aurora Pharmaceutical, a leading manufacturer of animal health products, is excited to announce the appointment of Stephanie Hastings as its new ...